E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: possible correlation with stage and treatment response

Mod Pathol. 2010 Nov;23(11):1507-17. doi: 10.1038/modpathol.2010.139. Epub 2010 Aug 27.

Abstract

Extranodal marginal-zone lymphoma of mucosa-associated lymphoid tissue of the stomach (gastric MALT lymphoma) is derived from memory B cells of the marginal zone. Normal memory B cells do not express markers of germinal-center B cells, such as E2A (immunoglobulin enhancer-binding factor E12/E47), B-cell chronic lymphocytic leukemia/lymphoma 6 (BCL6), or activation-induced cytidine deaminase (AID). E2A is a transcription factor that induces somatic hypermutations and blocks plasma cell differentiation. In 50 stage-I(E)/II(E1) gastric MALT lymphomas, we confirmed that all cases were BCL6(-)/AID(-), but a subset (50%, 25/50) was E2A(+). As E2A(-) and E2A(+) gastric MALT lymphomas had similar numbers of somatic hypermutations without intraclonal variations, which implied an origin from memory B cells, the expression of E2A was best regarded as a marker of aberrant follicular differentiation. Although the status of somatic hypermutation was not affected by E2A, E2A(+) gastric MALT lymphoma showed less plasmacytoid infiltrates and higher expressions of miRNA-223, a microRNA associated with memory B cells. Clinically, E2A(+) gastric MALT lymphomas were more likely to spread to perigastric lymph nodes and were less responsive to Helicobacter eradication therapy than were E2A(-) gastric MALT lymphomas. Taken together, aberrant E2A expression is a diagnostic feature of a subtype of gastric MALT lymphoma with weaker plasmacytoid infiltrates and stronger miR-223 expression. A prospective study would be necessary to verify the association between E2A expression and a poor response to Helicobacter eradication therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • B-Lymphocytes / chemistry*
  • B-Lymphocytes / immunology
  • B-Lymphocytes / pathology
  • Basic Helix-Loop-Helix Transcription Factors / analysis*
  • Biomarkers, Tumor / analysis*
  • Biopsy
  • Cell Differentiation
  • Cluster Analysis
  • Cytidine Deaminase / analysis
  • DNA-Binding Proteins / analysis
  • Gene Expression Regulation, Neoplastic
  • Genes, Immunoglobulin Heavy Chain
  • Helicobacter Infections / drug therapy
  • Helicobacter Infections / microbiology
  • Helicobacter pylori / pathogenicity
  • Humans
  • Immunohistochemistry
  • Immunologic Memory*
  • Lymph Nodes / chemistry*
  • Lymph Nodes / immunology
  • Lymph Nodes / pathology
  • Lymphoma, B-Cell, Marginal Zone / chemistry*
  • Lymphoma, B-Cell, Marginal Zone / genetics
  • Lymphoma, B-Cell, Marginal Zone / immunology
  • Lymphoma, B-Cell, Marginal Zone / microbiology
  • Lymphoma, B-Cell, Marginal Zone / pathology
  • Lymphoma, B-Cell, Marginal Zone / therapy
  • MicroRNAs / analysis*
  • Mutation
  • Neoplasm Staging
  • Plasma Cells / chemistry*
  • Plasma Cells / immunology
  • Plasma Cells / pathology
  • Proto-Oncogene Proteins / analysis
  • Proto-Oncogene Proteins c-bcl-6
  • Retrospective Studies
  • Reverse Transcriptase Polymerase Chain Reaction
  • Stomach Neoplasms / chemistry*
  • Stomach Neoplasms / genetics
  • Stomach Neoplasms / immunology
  • Stomach Neoplasms / microbiology
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / therapy
  • Taiwan
  • Treatment Outcome

Substances

  • BCL6 protein, human
  • Basic Helix-Loop-Helix Transcription Factors
  • Biomarkers, Tumor
  • DNA-Binding Proteins
  • MIRN223 microRNA, human
  • MicroRNAs
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-6
  • TCF3 protein, human
  • TCL1A protein, human
  • AICDA (activation-induced cytidine deaminase)
  • Cytidine Deaminase